Craiova

• A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil … Not authorised
  2022-501361-44-00 5 Adult patients of either gender with active moderate to severe rheumat
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infe … Pending
  2024-518420-80-00 5 Primary infection prophylaxis for secondary immunodeficiency (SID) in
• REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending
  2024-519298-21-00 5 Cancer-Associated Thrombosis (CAT).
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Pending
  2025-520565-51-00 5 small cell lung cancer
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending
  2025-521950-41-00 5 severe uncontrolled asthma
• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Pending
  2025-522204-24-00 4 Drug-Related Side Effects and Adverse Reactions
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr … Pending
  2025-522983-33-00 5 Chronic rhinosinusitis with nasal polyps
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending
  2025-523586-18-00 5 Non-Small Cell Lung Cancer
• A study of BMN 333 versus Vosoritide in Children with Achondroplasia Pending
  2025-523811-12-00 10 Achondroplasia
• A Phase 1/2 Study of BMS-986525 with and without Nivolumab in Relapsed/Refractory Small Cell Lung Cancer Pending
  2025-524090-16-00 7 Relapsed/Refractory Small Cell Lung Cancer
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-21 Uncontrolled Moderate to Severe Eosinophilic Asthma
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos … Recruiting
  2024-511496-14-00 5 2026-05-14 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors Recruiting
  2025-523742-27-00 9 2026-04-28 Advanced solid tumors
• Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study Recruiting
  2025-523803-31-00 4 2026-04-16 Advanced non-small cell lung cancer (NSCLC)
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia

Showing 1–24 of 313 trials